In part two of a commentary series for Pharmacy Times, RxBenefits Chief Pharmacy Officer Mark Campbell, PharmD, explores the challenges that have prevented biosimilars from delivering on their cost-saving promise.
Campbell highlights how formulary design and the behavioral psychology behind it have played a significant role in this story, resulting in prescribers and patients having to navigate a dense jungle of price points, rebates, and confusing tier placements.
Key Highlights:
- The complex market dynamics preventing biosimilar uptake
- The role of PBM formularies in maintaining high costs
- Why biosimilars have not generated the expected savings
- What needs to change for biosimilars to fulfill their potential
Did you miss the first article? No problem, catch up by reading the article here.
